Beacon Intelligence：2025中国抗体偶联药物（ADC）研发的崛起研究报告（中译版）（21页）.pdf

《Beacon Intelligence：2025中国抗体偶联药物（ADC）研发的崛起研究报告（英文版）（21页）.pdf》由会员分享，可在线阅读，更多相关《Beacon Intelligence：2025中国抗体偶联药物（ADC）研发的崛起研究报告（英文版）（21页）.pdf（21页珍藏版）》请在三个皮匠报告上搜索。

1、Chinas Rise in ADC Developmentbeacon-2beacon-Chinas Rise in ADC Development About BeaconOur platform combines proprietary,market-defining ontologies with the most accurate and comprehensive life sciences data,offering unparalleled visibility into the drug,clinical trial,and commercial landscapes.The

2、 sheer scope of ADC drug development makes it increasingly difficult to keep track of key players,pipeline activity,novel technologies,and their results.Beacon provides a clear solution,offering real-time,expert-curated insights across the entire global landscape.As of November 2025,Beacon ADC track

3、s over 3,800 drugs,4,300 trials,3,000 deals,and 2,500 companies,delivering unmatched visibility across both emerging and established pipelines.Beacon empowers the worlds leading pharma and biotech companies to bring their innovative therapeutics to market faster.About Beacon2 About Beacon3 Introduct

4、ion5 Drug landscape9 Trial landscape13 Commercial Landscape21 Summary*Other ADCs:Small-molecule conjugates(SMDCs,peptide,protein,oligonucleotide),Nanoparticle conjugates(antibody-nanoparticle,small-molecule-nanoparticle),Liposomal conjugates,Radioconjugates,Radioimmunoconjugates 3beacon-Chinas Rise

5、in ADC Development IntroductionAcross the global ADC landscape,traditional,bispecific,and dual-payload ADCs comprise more than half of all assets,making these three modalities the focus of this digest.Chinas participation is substantial,accounting for 25%of all assets in these categories,with an esp

6、ecially strong presence in next-generation modalities:54%of bispecific ADCs and 38%of dual-payload ADCs involve Chinese developers.China is firmly established in traditional ADC development,with 50%(9/18)of approved ADCs worldwide linked to Chinese companies.While most China-associated dual-payload